Azar Tahghighi | Molecular Docking & Molecular Dynamic | Research Excellence Award

Published on by Network Science

Research Excellence Award

Azar Tahghighi
Pastur Institute of Iran
Azar Tahghighi
Affiliation Pastur Institute of Iran
Country Iran
Scopus ID 24923832500
Documents 47
Citations 728
h-index 15
Subject Area Molecular Docking & Molecular Dynamic
Event International Research Awards on Network Science & Graph Analytics
ORCID 0000-0002-1221-4490

Azar Tahghighi is a researcher affiliated with the Pastur Institute of Iran whose scholarly activities span molecular docking, molecular dynamics simulations, medicinal chemistry, antimicrobial discovery, and computational drug design. Her body of work integrates in silico methodologies with experimental validation to investigate biologically active compounds, receptor-ligand interactions, and novel therapeutic candidates. Through contributions to peer-reviewed scientific literature, she has participated in advancing contemporary approaches for drug discovery and biological target identification.[1]

Abstract

This article summarizes the academic achievements and research contributions of Azar Tahghighi in the fields of medicinal chemistry and computational molecular sciences. Her research portfolio emphasizes molecular docking, molecular dynamics, pharmacophore modeling, antimicrobial agent discovery, and receptor-targeted therapeutic development. By combining computational prediction with laboratory validation, her work contributes to the identification of biologically relevant compounds and supports contemporary drug discovery strategies.[2]

Keywords

Molecular Docking, Molecular Dynamics, Medicinal Chemistry, Drug Discovery, TLR7 Ligands, Pharmacophore Modeling, Antibacterial Agents, Antibiofilm Activity, Computational Biology, Virtual Screening.

Introduction

Modern pharmaceutical research increasingly relies on computational techniques to accelerate therapeutic discovery and optimize candidate selection. Azar Tahghighi’s research aligns with this interdisciplinary trend by integrating computational chemistry, structural biology, and medicinal chemistry approaches. Her studies frequently investigate molecular interactions and biological pathways relevant to infectious diseases, immune modulation, and antimicrobial resistance.[3]

Research Profile

According to available scholarly metrics, the researcher has produced 47 indexed documents, accumulated 728 citations, and achieved an h-index of 15. Her scientific activities encompass molecular docking, molecular dynamic simulations, synthetic medicinal chemistry, receptor-targeted drug design, and antimicrobial evaluation. These contributions reflect sustained engagement with computational and experimental biomedical research.[1]

Research Contributions

  • Development of novel triazoloquinoxaline derivatives targeting Toll-like receptor 7.
  • Application of pharmacophore-based virtual screening and molecular docking techniques.
  • Investigation of antibacterial and antibiofilm compounds against resistant pathogens.
  • Research on probiotic-derived antibacterial extracts and microbial control strategies.
  • Evaluation of green chemistry approaches for antifungal drug synthesis.

Publications

  • Structure-guided design of triazolo[4,3-a] quinoxaline-4-ol derivatives as novel TLR7 ligands (2026).
  • Identification of new triazoloquinoxaline amine derivatives against Toll-like receptor 7 (2025).
  • Antibacterial and Antibiofilm Efficacy against MRSA (2025).
  • Click chemistry for green synthesis of antifungal medications (2024).
  • Anti-bacterial and anti-biofilm activity of probiotic Lactobacillus extracts (2024).

Research Impact

The research output demonstrates the practical application of computational methodologies for identifying promising therapeutic candidates. Publications addressing immune receptor modulation, antimicrobial resistance, and medicinal chemistry contribute to scientific understanding in areas of ongoing biomedical importance. Citation performance further indicates that her work has received recognition within relevant academic communities.[4]

Award Suitability

Azar Tahghighi’s multidisciplinary research profile demonstrates sustained scholarly productivity, measurable citation impact, and active engagement in computational and experimental biomedical sciences. Her contributions to molecular modeling, medicinal chemistry, and antimicrobial research align with the principles of research excellence recognized by international scientific award programs. The combination of publication quality, innovation, and translational relevance supports consideration for academic recognition.[5]

Conclusion

Azar Tahghighi has established a research portfolio focused on computational drug discovery, medicinal chemistry, and antimicrobial innovation. Through a combination of molecular modeling techniques and laboratory-based investigations, her work contributes to advancing therapeutic development and biological target evaluation. These accomplishments reflect a meaningful contribution to contemporary biomedical research and scientific scholarship.[6]

References

  1. Elsevier. (n.d.). Scopus author details: Azar Tahghighi, Author ID 24923832500. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=24923832500
  2. Chemical Physics Impact. (2026). Structure-guided design of triazolo[4,3-a] quinoxaline-4-ol derivatives as novel TLR7 ligands.
    https://doi.org/10.1016/j.chphi.2026.101045
  3. PLOS One. (2025). Identification of new triazoloquinoxaline amine derivatives with potent modulatory effects against Toll-like receptor 7.
    https://doi.org/10.1371/journal.pone.0336701
  4. Journal of Medical Microbiology and Infectious Diseases. (2025). Antibacterial and Antibiofilm Efficacy of a Synthetic Nitrofuranyl Pyranopyrimidinone Derivative.
    https://doi.org/10.61882/JoMMID.13.2.139
  5. Chemical Biology & Drug Design. (2024). Click chemistry beyond metal-catalyzed cycloaddition as a tool for antifungal medication synthesis.
    https://doi.org/10.1111/cbdd.14555
  6. Iranian Biomedical Journal. (2024). Evaluation of Anti-Bacterial and Anti-Biofilm Activity of Native Probiotic Strains of Lactobacillus Extracts.
    https://doi.org/10.61186/ibj.4043

Essa M. Saied | Pharmaceutical Sciences | Research Excellence Award

Published on by Network Science

Dr. Essa M. Saied | Pharmaceutical Sciences | Research Excellence Award

Humboldt University of Berlin | Germany

Dr. Essa M. Saied is a distinguished Senior Researcher in the Bioorganic Chemistry Department at Humboldt University of Berlin, Germany, and an Associate Professor of Biochemistry in the Chemistry Department at Suez Canal University, Egypt. His research spans the fields of bioorganic and biochemistry with strong expertise in synthetic medicinal chemistry, heterocyclic chemistry, small-molecule drug discovery, high-throughput screening, molecular modelling, virtual screening, enzymatic assays, anticancer research, and lipid chemistry in human diseases. He earned his Ph.D. in Organic and Bioorganic Chemistry from Humboldt-Universität zu Berlin in 2017 with a thesis on “Synthesis and Characterization of Inhibitors of Sphingolipid Metabolism,” following a Master of Science in Organic Chemistry from Suez Canal University with an excellent grade and earlier pre-master coursework in Organic, Physical, and Inorganic Chemistry. Dr. Saied has secured several competitive grants and fellowships, including the Yousef Jameel Ph.D. Fellowship, the EXIST-Gründerstipendium for the “Lipotools – Lipids in Focus of Pharmacological Drug Development” startup, the Royal Chemical Society Researcher Development Grant, and funding from the Deanship for Research & Innovation, Ministry of Education in Saudi Arabia. His professional experience reflects a strong international footprint, serving as a senior researcher in Berlin since 2017, a visiting scientist at Children’s Cancer Hospital Egypt (57357), and a former CEO of the “Lipotools” startup, alongside progressive academic roles in Suez Canal University. His major scientific interests include drug synthesis and development, small-molecule screening, computer-aided drug design, development of biochemical and enzymatic tools, lipid-based disease research, and drug repurposing to treat human diseases.

Profiles: Scopus | Orcid | Google Scholar

Featured Publications

"Dyslipidemic SPTLC3 Integrates Bile Acid-FXR Signaling with Sphingolipid Remodeling in MASLD", M Visentin, Z Gai, A Kovilakath, F De Luca, G Panteloglou, A Othman, bioRxiv, 2025.

"Editorial on research topic Medicinal Chemistry for Neglected Tropical Diseases Using In-vitro, In-vivo and In Silico Approaches", SN Mali, EM Saied, CBR Dos Santos, J Neves Cruz, Frontiers in Chemistry 13, 2025.

"Integrative Metabolomic, Network Pharmacology, and Experimental Evidence for Lepidium sativum Seed Extract as a Natural Modulator of Pulmonary Fibrosis via the ncNRFR/Let-7d", IM Alanazi, HH Abo Nahas, DI Mohamed, N Hosny, YHA Elewa, Pharmaceuticals 18 (12), 2025.

"Multi-targeted azacoumarin–cyanocinnamate hybrids induce G 2/M arrest and apoptosis via tubulin, and COX-2/VEGFR modulation: insights from in vitro mechanistic basis", MA El-Zend, IM El-Deen, RM Mansour, TA Yousef, AA Alrashidi, RSC Medicinal Chemistry, 2025.

"Exploration of the anticancer efficacy of a novel 1, 3-thiazole analog in an ehrlich ascites carcinoma model: in vivo and in silico insights into hepatorenal protective", M El Behery, DM Abo-Elmatty, M Alsunbul, YIM El-Deen, DI Mohamed, RSC advances 15 (25), 2025.